Last Updated : July 24, 2024
Details
Generic Name:
fluticasone furoate/umeclidinium bromide/vilanterol trifenatate
Project Status:
Not filed
Therapeutic Area:
Asthma, maintenance
Manufacturer:
GlaxoSmithKline Inc.
Brand Name:
Trelegy Ellipta
Project Line:
Reimbursement Review
Project Number:
NS0025-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
Long-term, once-daily, maintenance treatment of asthma in patients aged 18 years and older who are not adequately controlled with a maintenance combination of a medium or high dose of an ICS and a LABA.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024